Alimentary TractLong-term nonsurgical management of Barrett's esophagus with high-grade dysplasia*,**
Section snippets
The program
From January 1979 to July 1996, patients with Barrett's esophagus were diagnosed in the ambulatory outpatient endoscopy clinic at Hines Veterans Affairs Hospital, Hines, Illinois. The clinic developed an organized patient recall system and used a full-time computer data entry person. From July 1996 through June 2000, screening and surveillance were continued in the combined inpatient/outpatient endoscopy clinic.
Endoscopy protocol
Patients with HGD underwent endoscopies and biopsies that were performed by 1 of 2
Results
During the 20 years of screening and surveillance, 1099 patients had Barrett's esophagus ranging from no dysplasia to cancer, and 26 patients had cancer of the gastroesophageal junction (non–Barrett's esophagus). Figure 2 shows the distribution of the 1125 patients at their current most advanced stage of dysplasia.
Discussion
Based on the results of our 20 years of screening, surveillance, and follow up of 75 patients with HGD existing alone, we suggest that the recommendation for esophagectomy in patients with HGD be reconsidered. Indeed, during surveillance for up to 13.9 years, only 12 (16%) eventually developed cancer. Eleven of the 12 patients complied with appropriate surveillance; 10 of the 11 had curable early cancer (only 1 patient had greater than stage I cancer but was still cured), and 1 refuses
Conclusions
We conclude that in patients with Barrett's esophagus and HGD without apparent cancer, frequent endoscopic surveillance with biopsies, rather than esophagectomy, is a valid and safe follow-up strategy for most patients with HGD without cancer, providing that 1 year of intensive endoscopic searching fails to detect cancer. Although management must be individualized, surgical resection of the esophagus should be reserved for those patients in whom cancer has been documented by biopsy.
Acknowledgements
The authors thank Jean Karpf, Gabe Levine, Shannon Reid, and Lawrence Brand.
References (19)
- et al.
Is Barrett's esophagus with high-grade dysplasia an indication for esophagectomy?
Ann Thorac Surg
(1992) - et al.
Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients
J Thorac Cardiovasc Surg
(1994) - et al.
Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia
Gastrointest Endosc
(1999) - et al.
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
Gastroenterology
(1993) - et al.
Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
Gastroenterology
(1993) - et al.
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications
Hum Pathol
(1983) - et al.
Observer variation in the diagnosis of dysplasia in Barrett's esophagus
Hum Pathol
(1988) - et al.
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
N Engl J Med
(1999) Pathogenesis of columnar cell lined (Barrett's) esophagus
Cited by (551)
Barrett's Esophagus and Associated Dysplasia
2024, Gastroenterology Clinics of North AmericaDNA flow cytometry for detection of genomic instability as a cancer precursor in the gastrointestinal tract
2024, Methods in Cell BiologyOptimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrett's Esophagus: An International Cohort Study
2022, Clinical Gastroenterology and HepatologyIs non-invasive Cytosponge the holy grail for Barrett's neoplasia?
2022, The Lancet OncologyRisk of Malignancy in Adenomas Detected During Screening Colonoscopy
2018, Clinical Gastroenterology and HepatologyCitation Excerpt :The use of HGD as a surrogate marker for the risk of cancer developing from adenomas seems to be established, based on the concept of the adenoma-carcinoma sequence,25 although it is not fully known how long HGD persists before it develops into carcinoma, or to what extent this is related to other factors. There is better evidence for an increased risk of cancer development from HGD in the upper gastrointestinal tract.26–28 However, 2 recent meta-analyses that analyzed the risk of recurrence in relation to histologic parameters in the colon found that HGD had a higher risk of advanced neoplasia at follow-up than other histologic parameters, such as villous histology.18,29
Neoplastic precursor lesions of the upper gastrointestinal tract
2017, Diagnostic Histopathology
- *
Address requests for reprints to: Thomas G. Schnell, M.D., Department of Veterans Affairs, Edward Hines, Jr., Hospital, Building No. 1, Room B321 (151B3), Hines, Illinois 60141. Fax: (708) 865-2048.
- **
This work was funded entirely by the Department of Veteran's Affairs.